JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB143839

Necrosulfonamide, necroptosis inhibitor

Be the first to review this product! Submit a review

|

(15 Publications)

MW 461.5 Da, Purity >98%. Potent, selective necroptosis inhibitor (IC50 = 0.2 μM). MLKL blocker. Selectively blocks necrosis downstream of RIP3 activation. Shows selective antinecrotic effects.
1 Images
Chemical Structure - Necrosulfonamide, necroptosis inhibitor (AB143839)
  • Chemical Structure

Lab

Chemical Structure - Necrosulfonamide, necroptosis inhibitor (AB143839)

2D chemical structure image of ab143839, Necrosulfonamide, necroptosis inhibitor

Key facts

CAS number

432531-71-0

Purity

>98%

Form

Solid

form

Molecular weight

461.5 Da

Molecular formula

C<sub>1</sub><sub>8</sub>H<sub>1</sub><sub>5</sub>N<sub>5</sub>O<sub>6</sub>S<sub>2</sub>

PubChem

1566236

Nature

Synthetic

Solubility

Soluble in DMSO to 25 mM

Biochemical name

Necrosulfonamide

Biological description

Potent, selective necroptosis inhibitor (IC50 = 0.2 μM). MLKL blocker. Selectively blocks necrosis downstream of RIP3 activation. Shows selective antinecrotic effects.

Canonical smiles

COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)NC(=O)C=CC3=CC=C(S3)[N+](=O)[O-]

Isomeric smiles

COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)NC(=O)/C=C/C3=CC=C(S3)[N+](=O)[O-]

InChi

InChI=1S/C18H15N5O6S2/c1-29-18-17(19-10-11-20-18)22-31(27,28)14-6-2-12(3-7-14)21-15(24)8-4-13-5-9-16(30-13)23(25)26/h2-11H,1H3,(H,19,22)(H,21,24)/b8-4+

InChiKey

FNPPHVLYVGMZMZ-XBXARRHUSA-N

IUPAC Name

(E)-N-[4-[(3-methoxypyrazin-2-yl)sulfamoyl]phenyl]-3-(5-nitrothiophen-2-yl)prop-2-enamide

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
It is important to note that this product is reported to be light sensitive|Store in the dark|Store under desiccating conditions

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MLKL also known as mixed lineage kinase domain-like protein plays a critical role in the process of necroptosis a form of programmed cell death. The MLKL protein has a molecular weight of approximately 54 kDa. The protein exists mainly within the cytoplasm but translocates to the plasma membrane during cell death execution. Expression of MLKL happens in various tissues indicating its wide biological importance. Phosphorylation of MLKL often referred to as p-MLKL is key to triggering its activity marking the transition from an inactive to an active state during necroptosis.
Biological function summary

The MLKL protein acts as an executioner of cell death by forming a complex that disrupts the plasma membrane integrity. This process is downstream of receptor-interacting serine/threonine-protein kinase 3 (RIPK3) which phosphorylates MLKL to form the active necrosome complex. Active MLKL oligomerizes and migrates towards the inner leaflet of the plasma membrane binding to phosphatidylinositol phosphates which assists in pore formation and cellular rupture. The ability to measure MLKL activity levels such as via MLKL ELISA kits is important for understanding necrotic processes in detailed studies.

Pathways

MLKL is integrally involved in the necroptotic pathway alongside RIPK1 and RIPK3 which are key initiators of necroptosis. Phosphorylated MLKL acts downstream of RIPK3 resulting in cell death without caspase activation distinguishing necroptosis from apoptosis. MLKL and RIPK3 are tightly linked within this pathway with MLKL phosphorylation serving as a vital event for the execution phase. The necroptosis pathway is part of larger networks including inflammatory response pathways highlighting the importance of MLKL's role beyond sheer cell death.

MLKL has been implicated in various inflammatory conditions and neurodegenerative diseases. The dysregulation of necroptosis can contribute to disorders such as inflammatory bowel disease and amyotrophic lateral sclerosis. In inflammatory bowel disease increased levels of p-MLKL might lead to excessive cell death exacerbating inflammation. Similarly in neurodegenerative disorders the harmful activation of MLKL may accelerate neuronal cell death. Key interactions with proteins like RIPK3 and RIPK1 highlight MLKL's involvement in these pathological processes making it a potential target for therapeutic intervention.

Product protocols

Publications (15)

Recent publications for all applications. Explore the full list and refine your search

International journal of biological sciences 21:3099-3121 PubMed40384863

2025

Regulating the balance between GSDMD-mediated pyroptosis and CHMP4B-dependent cell repair attenuates calcium oxalate kidney stone formation.

Applications

Unspecified application

Species

Unspecified reactive species

Shushuai Yang,Yuanjiong Qi,Yue Chen,Hailong Kong,Bin Han,Zhongsheng Peng,Chenglong Xu,Bohan Wang,Liqun Chen,Shiyong Qi

Cell death & disease 15:867 PubMed39616223

2024

GEFT inhibits the GSDM-mediated proptosis signalling pathway, promoting the progression and drug resistance of rhabdomyosarcoma.

Applications

Unspecified application

Species

Unspecified reactive species

Fan Yang,Tian Xia,Zhijuan Zhao,Jinyang Lin,Ling Zhong,Tian Tang,Degui Liao,Miaoling Lai,Jiamin Ceng,Lian Meng,Feng Li,Chunxia Liu

BMC oral health 24:773 PubMed38987730

2024

Effect and mechanism of resveratrol on ferroptosis mediated by p53/SLC7A11 in oral squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Chen Mao,Liqiang Gong,Wenming Kang

Human molecular genetics 33:1506-1523 PubMed38776958

2024

PSMC5 insufficiency and P320R mutation impair proteasome function.

Applications

Unspecified application

Species

Unspecified reactive species

Zhong-Qiu Yu,Jenny Carmichael,Galen A Collins,Maria Daniela D'Agostino,Mathieu Lessard,Helen V Firth,Pooja Harijan,Andrew E Fry,John Dean,Jiuchun Zhang,Usha Kini,Alfred L Goldberg,David C Rubinsztein

iScience 27:109580 PubMed38600973

2024

Necrosulfonamide causes oxidation of PCM1 and impairs ciliogenesis and autophagy.

Applications

Unspecified application

Species

Unspecified reactive species

Clotilde C N Renaud,Carolina Alves Nicolau,Clément Maghe,Kilian Trillet,Jane Jardine,Sophie Escot,Nicolas David,Julie Gavard,Nicolas Bidère

Oncology reports 50: PubMed37711054

2023

Circular RNA circBLNK promotes osteosarcoma progression and inhibits ferroptosis in osteosarcoma cells by sponging miR‑188‑3p and regulating GPX4 expression.

Applications

Unspecified application

Species

Unspecified reactive species

Zhongjun Li,Yi Luo,Chunbo Wang,Dunxin Han,Weiping Sun

iScience 26:106523 PubMed37123232

2023

Progesterone prevents HGSOC by promoting precancerous cell pyroptosis via inducing fibroblast paracrine.

Applications

Unspecified application

Species

Unspecified reactive species

Nayiyuan Wu,Xiaoye Zhang,Zhibin Wang,Xiu Zhang,Chao Fang,He Li,Miaochen Zhu,Ying Wang,Qianjin Liao,Tang-Yuan Chu,Jing Wang

iScience 25:105118 PubMed36185361

2022

Inhibition of the pseudokinase MLKL alters extracellular vesicle release and reduces tumor growth in glioblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Gwennan André-Grégoire,Clément Maghe,Tiphaine Douanne,Sara Rosińska,Fiorella Spinelli,An Thys,Kilian Trillet,Kathryn A Jacobs,Cyndie Ballu,Aurélien Dupont,Anne-Marie Lyne,Florence M G Cavalli,Ignacio Busnelli,Vincent Hyenne,Jacky G Goetz,Nicolas Bidère,Julie Gavard

Translational oncology 13:372-382 PubMed31887632

2019

Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Qiong Wang,Peipei Wang,Li Zhang,Mathewos Tessema,Lang Bai,Xiuling Xu,Qin Li,Xuelian Zheng,Bryanna Saxton,Wenshu Chen,Randy Willink,Zhiping Li,Lin Zhang,Steven A Belinsky,Xia Wang,Bin Zhou,Yong Lin

Molecular brain 12:78 PubMed31533781

2019

miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2.

Applications

Unspecified application

Species

Unspecified reactive species

Xiao Xiao,Youjing Jiang,Weibo Liang,Yanyun Wang,Shuqiang Cao,He Yan,Linbo Gao,Lin Zhang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com